etidronate and Hangman Fracture studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Research Excerpts

Excerpt	Relevance	Reference
"5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan."	9.10	A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002)
"The purpose of the present study was to compare the effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living (ADL) in elderly women with vertebral fractures."	9.10	Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003)
"A 3 year prospective randomized study was conducted to clarify the efficacy of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis."	9.10	Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. ( Fujii, T; Hirakata, M; Kuwana, M; Mimori, T; Nakamura, K; Nojima, T; Ohosone, Y; Sato, S; Suwa, A; Yasuoka, H, 2003)
"Clinical experience with cyclical etidronate for the treatment of osteoporosis was reviewed in 69 consecutive patients."	9.07	Clinical experience with etidronate in osteoporosis. ( Fogelman, I; Ryan, PJ, 1994)
"Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan."	8.84	[Evidence and utility of etidronate for the treatment of osteoporosis]. ( Iba, K; Takada, J; Yamashita, T; Yoshizaki, T, 2008)
"A case of osteogenesis imperfecta (OI) that was successfully treated with oral etidronate and alfacalcidol is reported."	7.72	Effects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case report. ( Ichimura, S; Iwamoto, J; Matsu, K; Takeda, T; Uzawa, M, 2003)
"In an open prospective study, we evaluated differences between patients with (wRVF group) and without recurrence of vertebral fracture (woRVF group) during cyclical etidronate therapy for osteoporosis."	7.70	Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation. ( Alexandre, C; Barou, O; Lafage-Proust, MH; Thomas, T; Vico, L, 1999)
"Osteoporosis is a recognized complication of corticosteroid therapy."	6.68	Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. ( Adachi, JD; Bensen, WG; Brown, J; Chines, AA; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; Ste-Marie, LG; Tenenhouse, A, 1997)
"Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures."	5.29	Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. ( Kochman, ML; Melton, ME, 1994)
"The purpose of this open-labeled prospective study was to compare the treatment effects of cyclical etidronate and alendronate on the lumbar bone mineral density (BMD), bone resorption, and back pain in elderly women with osteoporosis."	5.11	Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005)
"5 mg daily risedronate in the treatment of involutional osteoporosis, the effect of risedronate on bone mineral density (BMD) of the lumbar spine was compared with that of etidronate, selected as a representative of the bisphosphonates currently marketed in Japan."	5.10	A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2002)
"The purpose of the present study was to compare the effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living (ADL) in elderly women with vertebral fractures."	5.10	Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003)
"A 3 year prospective randomized study was conducted to clarify the efficacy of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis."	5.10	Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. ( Fujii, T; Hirakata, M; Kuwana, M; Mimori, T; Nakamura, K; Nojima, T; Ohosone, Y; Sato, S; Suwa, A; Yasuoka, H, 2003)
"The purpose of the present study was to examine the early response of lumbar bone mineral density (BMD), bone resorption, and back pain to alendronate after treatment with cyclical etidronate in postmenopausal women with osteoporosis."	5.10	Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003)
"Clinical experience with cyclical etidronate for the treatment of osteoporosis was reviewed in 69 consecutive patients."	5.07	Clinical experience with etidronate in osteoporosis. ( Fogelman, I; Ryan, PJ, 1994)
"Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan."	4.84	[Evidence and utility of etidronate for the treatment of osteoporosis]. ( Iba, K; Takada, J; Yamashita, T; Yoshizaki, T, 2008)
"According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively."	4.81	[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001)
"To conduct a pooled data analysis in a group of patients defined by sex, menopausal status, and underlying disease in order to examine the effect of intermittent cyclical etidronate in the prevention and treatment of corticosteroid induced osteoporosis."	4.80	A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. ( Adachi, JD; Brown, J; Cawley, MI; Cooper, C; Dequeker, J; Geusens, P; Ioannidis, G; Jenkins, EA; Laan, RF; Moniz, C; Pack, S; Pitt, PI; Roux, C; Stephenson, GF; Walker-Bone, KE, 2000)
" Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures."	3.81	Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015)
"Treatment with alendronate was associated with significantly greater improvements in lumbar spine BMD within one year in breast cancer survivors when compared with treatment with cyclic etidronate or calcium and vitamin D."	3.73	Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? ( Adachi, JD; Boulos, P; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Kouroukis, T; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2005)
"A case of osteogenesis imperfecta (OI) that was successfully treated with oral etidronate and alfacalcidol is reported."	3.72	Effects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case report. ( Ichimura, S; Iwamoto, J; Matsu, K; Takeda, T; Uzawa, M, 2003)
"Calcium and vitamin D supplements and low cost bisphosphonate regimens such as cyclic etidronate decrease the life-time vertebral fracture risk at acceptable costs and should be considered when initiating glucocorticoid treatment for women who do not have osteoporosis."	3.72	A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. ( Buckley, LM; Hillner, BE, 2003)
"In an open prospective study, we evaluated differences between patients with (wRVF group) and without recurrence of vertebral fracture (woRVF group) during cyclical etidronate therapy for osteoporosis."	3.70	Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation. ( Alexandre, C; Barou, O; Lafage-Proust, MH; Thomas, T; Vico, L, 1999)
"Inhibition of skeletal mineralisation is a well-recognized complication of disodium etidronate therapy that was identified in the earliest studies of its use in osteoporosis and Paget's disease."	3.70	Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. ( MacGowan, JR; Morris, VH; Pringle, J; Stamp, TC, 2000)
"to investigate the effects of oral intermittent cyclical etidronate therapy on bone mineral density (BMD) in men with idiopathic vertebral osteoporosis."	3.69	Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. ( Anderson, FH; Bishop, JC; Francis, RM; Rawlings, DJ, 1997)
" In conclusion, risedronate 75mg once-monthly (a dosage which is 30 times higher than risedronate 2."	2.79	Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. ( Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H, 2014)
"A total of 101 women with postmenopausal osteoporosis aged >60 years were randomly stratified into two groups-R group (n = 51), treated with risedronate alone; and R + K group (n = 50), treated with risedronate and vitamin K2."	2.79	Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. ( Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014)
" This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis."	2.78	A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. ( Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR, 2013)
" Risedronate 35 mg once a week is considered the optimal dose want a once-a-week dosing regimen."	2.71	Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. ( Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004)
" Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events."	2.69	Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. ( Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH, 2000)
"Five years of etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content, and the previously observed reduction in vertebral fracture rate in the etidronate group is maintained during at least 5 years of therapy."	2.68	Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. ( Genant, HK; Kollerup, G; Storm, T; Sørensen, OH; Thamsborg, G, 1996)
"Osteoporosis is a recognized complication of corticosteroid therapy."	2.68	Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. ( Adachi, JD; Bensen, WG; Brown, J; Chines, AA; Hanley, D; Hodsman, A; Josse, R; Kendler, DL; Lentle, B; Olszynski, W; Ste-Marie, LG; Tenenhouse, A, 1997)
" In these studies another formulation of the drug and other dosing instructions are used."	2.68	A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. ( Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B, 1997)
"The etidronate group was treated with etidronate 400 mg once daily for 14 days followed by 76 days of 500 mg of elementary calcium once daily; this cycle was repeated every 3 months."	2.68	The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. ( Bakker, K; Kerkhoff, JF; Montessori, ML; Netelenbos, JC; Scheele, WH, 1997)
"Male osteoporosis is an important public health issue and remains undertreated."	2.45	Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. ( Chen, JT; Zhong, ZM, 2009)
"Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture."	2.44	Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008)
"In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate."	2.43	[Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005)
"In recent years, treatments for osteoporosis have been developing rapidly, and many of these research results have been reported."	2.42	[Bone quality in treatment with raroxifene ]. ( Nakamura, T, 2004)
"Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation."	2.41	Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002)
"Hip fractures have been neglected."	2.39	Present and future of osteoporosis therapy. ( Bass, S; Pearce, G; Seeman, E; Tsalamandris, C, 1995)
"4), while the risk factor for OFH was a recent maximum GC dosage (>1."	1.35	Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. ( Amano, K; Kameda, H; Nagasawa, H; Ogawa, H; Sekiguchi, N; Suzuki, K; Takei, H; Takeuchi, T, 2009)
"Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment."	1.31	[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002)
"Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures."	1.29	Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. ( Kochman, ML; Melton, ME, 1994)
"In summary, increased bone resorption occurs after OLT with persistent decreased bone formation, leading to vertebral fracture in 25% of patients."	1.29	Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. ( Drent, G; Groen, EW; Haagsma, EB; Meerman, L; Oostdijk, A; Piers, DA; Riemens, SC; Slooff, MJ; Thijn, CJ; van Doormaal, JJ, 1996)

Research

Studies (139)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Technology (QCT) at 6 Months

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	26 (18.71)	18.2507
2000's	95 (68.35)	29.6817
2010's	18 (12.95)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Mhaskar, R	1
Kumar, A	1
Miladinovic, B	1
Djulbegovic, B	1
Nakamura, T	4
Nakano, T	1
Ito, M	1
Hagino, H	3
Hashimoto, J	1
Tobinai, M	1
Mizunuma, H	1
Tanaka, S	1
Miyazaki, T	1
Uemura, Y	1
Kuroda, T	1
Miyakawa, N	1
Fukunaga, M	4
Ohashi, Y	3
Ohta, H	1
Mori, S	1
Hosoi, T	1
Sugimoto, T	1
Itoi, E	1
Orimo, H	3
Shiraki, M	7
Kasukawa, Y	1
Miyakoshi, N	1
Ebina, T	1
Aizawa, T	1
Hongo, M	1
Nozaka, K	1
Ishikawa, Y	1
Saito, H	1
Chida, S	1
Shimada, Y	1
Kishimoto, H	6
Ohishi, H	1
Horii, S	1
Messori, A	1
Fadda, V	1
Maratea, D	1
Trippoli, S	1
Marinai, C	1
Reid, IR	2
Lems, WF	1
Geusens, PP	1
Hochberg, MC	1
Takada, J	2
Iba, K	2
Yamashita, T	2
Yoshizaki, T	1
Curtis, JR	1
Westfall, AO	1
Cheng, H	1
Saag, KG	2
Delzell, E	1
Zhong, ZM	1
Chen, JT	1
Wasserfallen, JB	1
Krieg, MA	1
Greiner, RA	1
Lamy, O	1
Kameda, H	1
Amano, K	1
Nagasawa, H	1
Ogawa, H	1
Sekiguchi, N	1
Takei, H	1
Suzuki, K	1
Takeuchi, T	1
Ohtori, S	1
Akazawa, T	1
Murata, Y	1
Kinoshita, T	1
Yamashita, M	1
Nakagawa, K	1
Inoue, G	1
Nakamura, J	1
Orita, S	1
Ochiai, N	1
Kishida, S	1
Takaso, M	1
Eguchi, Y	1
Yamauchi, K	1
Suzuki, M	1
Aoki, Y	1
Takahashi, K	1
Roux, C	5
Goldstein, JL	1
Zhou, X	2
Klemes, A	1
Lindsay, R	3
El Rachkidi, R	1
Sari-Leret, ML	1
Wolff, S	1
Guadalix, S	1
Martínez-Díaz-Guerra, G	1
Lora, D	1
Vargas, C	1
Gómez-Juaristi, M	1
Cobaleda, B	1
González, EM	1
Hawkins, F	2
Lee, JH	1
Lee, SH	1
Eastell, R	5
Hannon, RA	1
Wenderoth, D	2
Rodriguez-Moreno, J	1
Sawicki, A	1
Hadji, P	1
Zanchetta, JR	2
Russo, L	1
Recknor, CP	1
McKiernan, FE	1
Silverman, SL	1
Alam, J	1
Burge, RT	1
Krege, JH	1
Lakshmanan, MC	1
Masica, DN	1
Mitlak, BH	1
Stock, JL	1
Davey, DA	1
McClung, MR	4
Benhamou, CL	1
Man, Z	1
Tlustochowicz, W	1
Eusebio, R	1
Balske, AM	1
Matzkin, E	1
Olszynski, WP	4
Recker, R	1
Delmas, PD	1
Glüer, CC	1
Marin, F	1
Ringe, JD	3
Möricke, R	1
Papaioannu, N	1
Farahmand, P	1
Minisola, S	1
Martínez, G	1
Nolla, JM	1
Niedhart, C	1
Guañabens, N	1
Nuti, R	1
Martín-Mola, E	1
Thomasius, F	1
Kapetanos, G	1
Peña, J	1
Graeff, C	1
Petto, H	1
Sanz, B	1
Reisinger, A	1
Zysset, PK	1
Srivastava, M	1
Deal, C	1
Kushida, K	2
Taketani, Y	1
Minaguchi, H	1
Inoue, T	2
Morita, R	1
Morii, H	2
Yamamoto, K	2
Baranauskaite, A	1
Eriksen, EF	2
Melsen, F	2
Sod, E	1
Barton, I	5
Chines, A	3
Minne, HW	3
Pollähne, W	1
Pfeifer, M	1
Begerow, B	1
Hinz, C	1
Buckley, LM	1
Hillner, BE	1
Deal, CL	1
Miller, PD	3
Watts, NB	8
Josse, RG	2
Hamdy, RC	1
Hughes, RA	3
Manhart, MD	2
Calligeros, D	1
Felsenberg, D	2
Sorensen, OH	3
Crawford, GM	1
Mulder, H	1
Hosking, DJ	2
Gennari, C	1
Mellstrom, D	1
Pack, S	4
Cooper, C	4
Reginster, JY	2
Iwamoto, J	5
Matsu, K	1
Takeda, T	5
Ichimura, S	4
Uzawa, M	4
Ettinger, MP	1
Cranney, A	7
Waldegger, L	1
Zytaruk, N	2
Shea, B	5
Weaver, B	2
Papaioannou, A	3
Robinson, V	3
Wells, G	6
Tugwell, P	6
Adachi, JD	14
Guyatt, G	5
Sato, S	1
Ohosone, Y	1
Suwa, A	1
Yasuoka, H	1
Nojima, T	1
Fujii, T	1
Kuwana, M	1
Nakamura, K	1
Mimori, T	1
Hirakata, M	1
Seibel, MJ	1
Naganathan, V	1
Grauer, A	2
Naka, H	1
Ishii, S	1
Kobayashi, S	2
Takaoka, K	2
Seeman, E	2
Adachi, J	1
Jackson, RD	2
Songcharoen, S	1
Rizzoli, R	2
Di Munno, O	1
Horlait, S	1
Valent, D	1
Harris, ST	3
Li, Z	4
Chines, AA	5
Hanley, DA	4
Brown, JP	4
Kanis, JA	4
Borgstrom, F	2
Johnell, O	3
Jonsson, B	2
Itabashi, A	1
Kaneda, K	1
Nawata, H	1
Barton, IP	3
van Staa, TP	1
Mellström, DD	1
Goemaere, S	1
Johnson, TD	1
Ishida, Y	1
Kawai, S	1
Boonen, S	3
El-Hajj Fuleihan, G	1
Delmas, P	1
Bartl, R	1
Allali, F	1
Guedirra, N	1
Hajjaj-Hassouni, N	1
Dorst, A	1
Faber, H	1
Kipshoven, C	1
Rovati, LC	1
Setnikar, I	1
Palomba, S	1
Orio, F	1
Manguso, F	1
Falbo, A	1
Russo, T	1
Tolino, A	1
Tauchmanovà, L	1
Colao, A	1
Doldo, P	1
Mastrantonio, P	1
Zullo, F	1
Meredith, MP	2
Chesnut, CH	3
White, NJ	1
Perry, CM	1
Poole, KE	1
Warburton, EA	1
Reeve, J	1
Sawka, AM	1
Ioannidis, G	3
Thabane, L	1
Murray, TM	1
Sebaldt, RJ	2
Petrie, A	1
Tenenhouse, A	3
Goldsmith, CH	1
Boulos, P	1
Kouroukis, T	1
Sato, Y	1
Carlsson, A	1
Sintonen, H	1
Haentjens, P	1
Burge, R	1
Griffith, L	3
Krolicki, N	3
Robinson, VA	2
Shea, BJ	2
Waldegger, LM	1
Muschitz, C	1
Roschger, P	1
Patsch, J	1
Pollhammer, I	1
Koller, B	1
Klaushofer, K	1
Resch, H	1
McKeever, CD	2
Soen, S	1
Wells, GA	1
Peterson, J	2
Boucher, M	2
Coyle, D	2
Gärtner, R	1
Ryan, PJ	1
Fogelman, I	1
Compston, J	1
Worth, H	1
Stammen, D	1
Keck, E	1
Leidig-Bruckner, G	1
Genant, HK	4
Storm, T	3
Thamsborg, G	3
Bruckner, T	1
Sauer, P	1
Schilling, T	1
Soerensen, OH	1
Ziegler, R	1
Melton, ME	1
Kochman, ML	1
Hosie, G	1
Albert, S	1
Glynn, C	1
Marcus, R	1
Wasnich, RD	1
Ross, P	1
Licata, AA	1
Steiniche, T	1
Tsalamandris, C	1
Bass, S	1
Pearce, G	1
Francis, RM	2
Anderson, FH	2
Torgerson, DJ	1
Riemens, SC	1
Oostdijk, A	1
van Doormaal, JJ	1
Thijn, CJ	1
Drent, G	1
Piers, DA	1
Groen, EW	1
Meerman, L	1
Slooff, MJ	1
Haagsma, EB	1
Kollerup, G	1
Sørensen, OH	1
Montessori, ML	1
Scheele, WH	1
Netelenbos, JC	2
Kerkhoff, JF	1
Bakker, K	1
Bensen, WG	2
Brown, J	4
Hanley, D	1
Hodsman, A	2
Josse, R	3
Kendler, DL	3
Lentle, B	2
Olszynski, W	1
Ste-Marie, LG	2
Lyritis, GP	1
Tsakalakos, N	1
Paspati, I	1
Skarantavos, G	1
Galanos, A	1
Androulakis, C	1
Bishop, JC	1
Rawlings, DJ	1
Disla, E	1
Tamayo, B	1
Fahmy, A	1
Clemmesen, B	1
Ravn, P	1
Zegels, B	1
Taquet, AN	1
Christiansen, C	1
Thomas, T	1
Barou, O	1
Vico, L	1
Alexandre, C	1
Lafage-Proust, MH	1
Rosner, AJ	1
Grima, DT	1
Torrance, GW	1
Bradley, C	1
Willison, DJ	1
Hangartner, T	1
Keller, M	1
Hoseyni, MS	2
Axelrod, DW	1
Reginster, J	1
Hooper, M	1
Brandi, ML	1
Lund, B	1
Ethgen, D	1
Roumagnac, I	1
Reid, DM	3
Laan, RF	3
Sacco-Gibson, NA	1
Wenderoth, DH	1
Adami, S	2
Eusebio, RA	1
Devogelaer, JP	2
MacGowan, JR	1
Pringle, J	1
Morris, VH	1
Stamp, TC	1
Wallach, S	1
Cohen, S	1
Doherty, SM	1
Maricic, M	1
Rosen, C	1
Pitt, PI	1
Moniz, C	1
Dequeker, J	1
Cawley, MI	1
Jenkins, EA	1
Walker-Bone, KE	1
Stephenson, GF	2
Geusens, P	2
Papapoulos, SE	1
Compston, JE	1
Welch, V	2
Shiota, E	1
Tsuchiya, K	1
Yamaoka, K	1
Kawano, O	1
Anastassiades, TP	1
Hanly, JG	1
Jovaisas, A	1
Dias, R	1
Kruse, HP	1
McClung, M	1
Hodsman, AB	1
Emkey, RD	1
Bolognese, MA	1
Balske, A	1
Attie, MF	1
Smith, R	1
Bockman, RS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949]		860 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
Vertebral Fracture and Osteonecrosis of the Femoral Head Associated With High-dose Glucocorticoid Therapy[NCT00679978]		60 participants (Actual)	Observational	2001-01-31	Completed
Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men[NCT00503399]	Phase 3	92 participants (Actual)	Interventional	2007-07-31	Completed
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516]	Phase 4	26 participants (Actual)	Interventional	2011-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Least Squares (LS) Means were adjusted for age, baseline propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months

Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months

Intervention	milligram per cubic centimeter (mg/cm^3) (Least Squares Mean)
Teriparatide	4.31
Risedronate	2.52

Least Squares (LS) Means were adjusted for age, baseline serum aminoterminal propeptide of Type I procollagen (P1NP), fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 18 months

Change From Baseline in Anterior Bending and Axial Torsion by Finite Element Analysis in the 12th Thoracic Vertebra (T12) at 6 Months and 18 Months: Stiffness and Strength

Intervention	milligram per cubic centimeter (mg/cm^3) (Least Squares Mean)
Teriparatide	12.28
Risedronate	2.94

Anterior bending and axial torsion were measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months

Change From Baseline in Areal Bone Mineral Density (BMD) at Lumbar Spine, Femoral Neck, and Total Hip at 18 Months

Intervention	Newton/millimeter/radian (N/mm/rad) (Least Squares Mean)
	Anterior bending stiffness at 6 months	Anterior bending stiffness at 18 months	Axial torsion stiffness at 6 months	Axial torsion stiffness at 18 months	Anterior bending strength at 6 months	Anterior bending strength at 18 months	Axial torsion strength at 6 months	Axial torsion strength at 18 months
Risedronate	415705.0	233283.0	77830.7	56639.3	8827.2	4822.0	3664.0	2545.8
Teriparatide	664969.0	1209225.0	142902.9	279392.8	12490.9	26046.4	6127.7	14181.3

Dual x-ray absorptiometry (DXA) techniques validated this measurement at skeletal sites that are at risk of osteoporotic fracture, such as lumbar spine, femoral neck, and hip. (NCT00503399)
Timeframe: Baseline, 18 months

Change From Baseline in Axial Compression by Finite Element Analysis in the 12th Thoracic Vertebra (T12) at 6 Months and 18 Months: Stiffness and Strength

Intervention	grams per square centimeter (g/cm^2) (Mean)
	Lumbar spine (n=38; n=39)	Hip (n=38; n=37)	Femoral neck (n=38; n=37)
Risedronate	0.037	0.007	-0.007
Teriparatide	0.068	0.014	0.014

Axial compression was measured using HR-QCT-based finite element analysis to determine stiffness and strength of T12. Stiffness evaluated the strength of the vertebral body, defined as the slope of the initial step of the force-displacement curve. Strength of the vertebral body was evaluated under compressive loading conditions using computer simulation. LS Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months

Change From Baseline in High Resolution Quantitative Computerized Technology (HR-QCT) of Integral and Trabecular Bone Mineral Density (BMD) of the 12th Thoracic Vertebra (T12) at 6 Months and 18 Months

Intervention	Newton per millimeter (N/mm) (Least Squares Mean)
	Axial compression stiffness at 6 months	Axial compression stiffness at 18 months	Axial compression strength at 6 months	Axial compression strength at 18 months
Risedronate	407.6	363.7	313.6	209.4
Teriparatide	890.7	1973.9	580.7	1287.5

Three-dimensional (3-D) microstructure variables of T12 were assessed by HR-QCT. In contrast with regular QCT that assessed 3 millimeter (mm) slide thickness, HR-QCT used segmentation of 1 single vertebra with approximately 100 consecutive slides reconstructed at 300-400 micrometer (µm) slice increments covering the complete vertebral body. Least Squares (LS) Means were adjusted for age, baseline P1NP, fracture less than 12 months before study start, duration of prior bisphosphonate use, screening glucocorticoid dose, and cumulative glucocorticoid dose before and during the trial. (NCT00503399)
Timeframe: Baseline, 6 months, 18 months

Change From Baseline in Serum Aminoterminal Propeptide of Type I Procollagen (P1NP) at 3 Months, 6 Months, and 18 Months

Intervention	milligram per cubic centimeter (mg/cm^3) (Least Squares Mean)
	Integral BMD at 6 months	Integral BMD at 18 months	Trabecular BMD at 6 months	Trabecular BMD at 18 months
Risedronate	-1.91	0.68	-0.87	0.22
Teriparatide	-0.42	10.72	-0.70	9.53

P1NP was used as a serum biochemical marker of collagen synthesis, reflecting the formation of new osteoid. (NCT00503399)
Timeframe: Baseline, 3 months, 6 months, 18 months

Change From Baseline in Serum Type I Collagen Degradation Fragments (β-CTx) at 3 Months, 6 Months, and 18 Months

Intervention	micrograms per deciliter (μg/dL) (Least Squares Mean)
	P1NP at 3 months	P1NP at 6 months	P1NP at 18 months
Risedronate	-16.09	-16.50	-15.58
Teriparatide	27.33	52.55	28.48

β-CTx was used as a biochemical marker of bone turnover/resorption, reflecting collagen breakdown of the bone matrix. (NCT00503399)
Timeframe: 3, 6, 18 months

Number of Participants With Adverse Events (AEs)

Intervention	nanograms per deciliter (ng/dL) (Least Squares Mean)
	β-CTx at 3 months	β-CTx at 6 months	β-CTx at 18 months
Risedronate	-0.15	-0.14	-0.11
Teriparatide	0.12	0.25	0.03

Summary tables of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module. Fractures that occurred during the study were collected separately as an additional safety variable. The number of participants experiencing hypercalcemia was summarized for each treatment arm. Hypercalcemia was defined as a serum calcium level corrected for albumin of >2.7 millimole per liter (mmol/L) (10.8 milligram per deciliter [mg/dL]). (NCT00503399)
Timeframe: Baseline up to 18 months

Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) and Instant Vertebral Assessment (IVA) Scan

Intervention	participants (Number)
	Serious Adverse Events (SAEs)	Other Non-serious AEs	Fractures	Hypercalcemia
Risedronate	22	30	5	0
Teriparatide	13	22	0	0

BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Change From Baseline in Disease Activity Score 28 Joint Count C-Reactive Protein (DAS-28 CRP)

Intervention	grams/centimeters squared (g/cm^2) (Mean)
	Spine, Baseline	Spine, Change from Baseline at Month12	Femoral neck, Baseline	Femoral neck, Change from Baseline at Month 12
Control Arm	0.93	-0.002	0.73	-0.03
Teriparatide	0.91	0.06	0.68	0.03

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Change From Baseline in Joint Erosion Volume Measured by 3-Dimensional Computed Tomography (3D CT) Scan

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 12
Control Arm	2.73	-0.50
Teriparatide	2.66	0.42

Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Article	Year
Bisphosphonates in multiple myeloma: an updated network meta-analysis. The Cochrane database of systematic reviews, 2017, 12-18, Volume: 12 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonat	2017
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods. Journal of endocrinological investigation, 2014, Volume: 37, Issue:8 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosp	2014
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. Current osteoporosis reports, 2008, Volume: 6, Issue:3 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations	2008
[Evidence and utility of etidronate for the treatment of osteoporosis]. Clinical calcium, 2008, Volume: 18, Issue:10 Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fem	2008
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Clinical drug investigation, 2009, Volume: 29, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Follow	2009
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem	2012
Osteoporosis in elderly: prevention and treatment. Clinics in geriatric medicine, 2002, Volume: 18, Issue:3 Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H	2002
[Osteoporosis: diagnosis and treatment of vertebral fractures]. Medicina (Kaunas, Lithuania), 2002, Volume: 38, Issue:8 Topics: Age Factors; Aged; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Middle A	2002
Risedronate prevents hip fractures, but who should get therapy? Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:12 Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid	2002
Editorial: greater risk, greater benefit--true or false? The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:2 Topics: Calcium Channel Blockers; Etidronic Acid; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk	2003
Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Archives of internal medicine, 2003, Oct-13, Volume: 163, Issue:18 Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic	2003
Risedronate for the prevention and treatment of postmenopausal osteoporosis. The Cochrane database of systematic reviews, 2003, Issue:4 Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi	2003
[AOS-100]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Absorptiometry, Photon; Alendronate; Bone Density; Etidronic Acid; Humans; Mass Screening; Osteoporo	2004
[Treatment of osteoporosis with etidronate]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Adenosine Triphosphate; Arthralgia; Bone Density; Clinical Trials as Topic; Energy Metabolism; Etidr	2004
[Risedronate treatment for osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fra	2004
[VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteo	2004
[Treatment of osteoporosis combined with a bisphosphonate and vitamin D3]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Alendronate; Bone Density; Cholecalciferol; Drug Therapy, Combination; Etidronic Acid; Humans; Multi	2004
[Concurrent treatment of osteoporosis with bisphosphonate and vitamin K2]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Animals; Bone Density; Bone Resorption; Drug Therapy, Combination; Etidronic Acid; Humans; Osteoporo	2004
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2004, Volume: 15, Issue:11 Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Ac	2004
[Bone quality in treatment with raroxifene ]. Clinical calcium, 2004, Volume: 14, Issue:5 Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis	2004
Risedronate once a week. Treatments in endocrinology, 2003, Volume: 2, Issue:6 Topics: Bone Density; Calcium Channel Blockers; Drug Administration Schedule; Etidronic Acid; Female; Humans	2003
WITHDRAWN: Etidronate for treating and preventing postmenopausal osteoporosis. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:1 Topics: Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spinal Fractures	2007
WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:1 Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi	2007
[Concurrent treatment of osteoporosis including vitamin K]. Clinical calcium, 2007, Volume: 17, Issue:11 Topics: Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Drug Therapy, Combi	2007
[Evidence of risedronate for treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Evidenc	2007
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top	2007
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. The Cochrane database of systematic reviews, 2008, Jan-23, Issue:1 Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Osteo	2008
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. The Cochrane database of systematic reviews, 2008, Jan-23, Issue:1 Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Os	2008
[Osteoporosis in the elderly--diagnosis and treatment]. MMW Fortschritte der Medizin, 2005, Feb-17, Volume: 147, Issue:7 Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca	2005
Present and future of osteoporosis therapy. Bone, 1995, Volume: 17, Issue:2 Suppl Topics: Bone Density; Bone Development; Bone Resorption; Calcitonin; Calcitriol; Calcium, Dietary; Diphospho	1995
A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. The Journal of rheumatology, 2000, Volume: 27, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Double-Blind Method; Drug Administration Schedule; Eti	2000
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Annales de medecine interne, 2000, Volume: 151, Issue:6 Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers;	2000
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2001, Volume: 12, Issue:2 Topics: Aged; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Post	2001
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. Nederlands tijdschrift voor geneeskunde, 2001, Jul-14, Volume: 145, Issue:28 Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac	2001
Etidronate for treating and preventing postmenopausal osteoporosis. The Cochrane database of systematic reviews, 2001, Issue:4 Topics: Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spinal Fractures	2001
Review of risedronate in the treatment of osteoporosis. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:12 Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Pos	2001
[Bisphosphonates: pharmacology and use in the treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Alendronate; Bone Density; Bone Remodeling; Clinical Trials as Topic; Diphosphonates; Etidronic Acid	2002
[Risedronate: clinical usage]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; H	2002
Bone quality: getting closer to a definition. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:7 Topics: Animals; Bone Density; Etidronic Acid; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Risedron	2002
Bisphosphonate therapy for osteoporosis. Hospital practice (Office ed.), 1991, Mar-30, Volume: 26, Issue:3A Topics: Bone Density; Bone Regeneration; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; H	1991

Article	Year
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcified tissue international, 2013, Volume: 93, Issue:2 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; E	2013
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Journal of bone and mineral metabolism, 2014, Volume: 32, Issue:3 Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Glome	2014
Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. Journal of bone and mineral metabolism, 2014, Volume: 32, Issue:3 Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Incidence; Ost	2014
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Bone, 2014, Volume: 59 Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response Relati	2014
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:2 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation	2010
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:7 Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cholecalciferol; Et	2011
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:8 Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid	2012
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcified tissue international, 2013, Volume: 92, Issue:1 Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Admi	2013
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Euro	2013
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2002, Volume: 13, Issue:12 Topics: Adult; Aged; Biomarkers; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid	2002
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone, 2002, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Ag	2002
Risedronate prevents hip fractures, but who should get therapy? Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:12 Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid	2002
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:2 Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Incidence; Osteoporosis, Postmenopau	2003
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone, 2003, Volume: 32, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density; Confidence Intervals; Etidronic Acid; Female; Humans; Osteopo	2003
Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis. The Keio journal of medicine, 2003, Volume: 52, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Density; Calcium; Collagen; Collagen Type I; E	2003
Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup. The Journal of rheumatology, 2003, Volume: 30, Issue:12 Topics: Adult; Bone Density; Calcium Compounds; Connective Tissue Diseases; Drug Administration Schedule; Dr	2003
Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. The Keio journal of medicine, 2003, Volume: 52, Issue:4 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Resorption; Disabi	2003
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:2 Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteopo	2004
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Current medical research and opinion, 2004, Volume: 20, Issue:5 Topics: Aged; Analysis of Variance; Bone Density; Double-Blind Method; Etidronic Acid; Humans; Lumbar Verteb	2004
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. Journal of bone and mineral metabolism, 2004, Volume: 22, Issue:5 Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Height; Bone and Bones; Collagen; Collagen	2004
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 2004,Fall, Volume: 7, Issue:3 Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic	2004
Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcified tissue international, 2004, Volume: 75, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal;	2004
RETRACTED: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. The American journal of medicine, 2004, 10-15, Volume: 117, Issue:8 Topics: Adjuvants, Immunologic; Aged; Bone Density; Calcitonin; Estrogen Replacement Therapy; Etidronic Acid	2004
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:11 Topics: Aged; Aged, 80 and over; Bone Remodeling; Calcium Channel Blockers; Double-Blind Method; Etidronic A	2004
Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatology international, 2005, Volume: 25, Issue:4 Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Calcaneus; Calcium; Dietary Supplements;	2005
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:5 Topics: Absorptiometry, Photon; Aged; Anthropometry; Bone Density; Double-Blind Method; Etidronic Acid; Fema	2005
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:9 Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur; Femur Neck; Humans; I	2005
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging clinical and experimental research, 2005, Volume: 17, Issue:2 Topics: Bone Density; Double-Blind Method; Etidronic Acid; Humans; Meta-Analysis as Topic; Osteoporosis, Pos	2005
Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei medical journal, 2005, Dec-31, Volume: 46, Issue:6 Topics: Aged; Aged, 80 and over; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation	2005
Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008, Volume: 19, Issue:3 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Collag	2008
Clinical experience with etidronate in osteoporosis. Clinical rheumatology, 1994, Volume: 13, Issue:3 Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Femur	1994
Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. American journal of respiratory and critical care medicine, 1994, Volume: 150, Issue:2 Topics: Adrenal Cortex Hormones; Asthma; Bone Density; Calcium; Drug Therapy, Combination; Etidronic Acid; F	1994
Comparison of a semiquantitative and a quantitative method for assessing vertebral fractures in osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1994, Volume: 4, Issue:3 Topics: Etidronic Acid; Female; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Randomized Controlled T	1994
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. The American journal of medicine, 1993, Volume: 95, Issue:6 Topics: Analysis of Variance; Bone Density; Double-Blind Method; Drug Administration Schedule; Etidronic Aci	1993
Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1993, Volume: 8, Issue:2 Topics: Aged; Bone Density; Bone Remodeling; Bone Resorption; Double-Blind Method; Etidronic Acid; Female; H	1993
Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. The Journal of rheumatology, 1996, Volume: 23, Issue:9 Topics: Aged; Bone Density; Disease Progression; Double-Blind Method; Drug Administration Schedule; Etidroni	1996
The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1997, Volume: 7, Issue:1 Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium; Calcium, Dietary; Drug Therapy, Combination; Et	1997
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. The New England journal of medicine, 1997, Aug-07, Volume: 337, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Calcium Carbonate; Double-Blind Method; Drug Administr	1997
The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clinical rheumatology, 1997, Volume: 16, Issue:4 Topics: Aged; Bone Density; Calcitriol; Cohort Studies; Etidronic Acid; Female; Femoral Neck Fractures; Huma	1997
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1997, Volume: 7, Issue:5 Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Double-Blind Method	1997
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 1999, Oct-13, Volume: 282, Issue:14 Topics: Aged; Analysis of Variance; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Fema	1999
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2000, Volume: 11, Issue:1 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Australia; Bone Density; Calcium Channe	2000
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:6 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density; Consumer Product	2000
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcified tissue international, 2000, Volume: 67, Issue:4 Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Ca	2000
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2001, Volume: 6, Issue:2 Topics: Aged; Calcium Compounds; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Hydroxycholecalc	2001
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcified tissue international, 2001, Volume: 69, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers;	2001
Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry, 2001,Winter, Volume: 4, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Femur Neck; Glucocorticoids; Hip; Huma	2001
Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2001, Volume: 6, Issue:6 Topics: Absorptiometry, Photon; Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosi	2001
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcified tissue international, 2002, Volume: 71, Issue:2 Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dos	2002

Article	Year
Efficacy, effectiveness and side effects of medications used to prevent fractures. Journal of internal medicine, 2015, Volume: 277, Issue:6 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds;	2015
Osteoporosis in men. The New England journal of medicine, 2008, Aug-21, Volume: 359, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Osteoporosis;	2008
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:6 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F	2009
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective. Journal of medical economics, 2008, Volume: 11, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidr	2008
Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. Internal medicine (Tokyo, Japan), 2009, Volume: 48, Issue:22 Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Head Necrosis; Glucoco	2009
[Osteoporosis management in general practice. Preventing spontaneous bone fractures]. MMW Fortschritte der Medizin, 2010, Jul-01, Volume: 152, Issue:25-27 Topics: Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Fractures, Spo	2010
Atypical bilateral pedicle fracture in long-term bisphosphonate therapy. Spine, 2011, Dec-15, Volume: 36, Issue:26 Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Low Back Pain; Lumbar Verteb	2011
Multiple vertebral compression fractures associated with post partum osteoporosis. Journal of back and musculoskeletal rehabilitation, 2011, Volume: 24, Issue:2 Topics: Adult; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fractures, C	2011
Effect of stopping risedronate after long-term treatment on bone turnover. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:11 Topics: Aged; Bone Density; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur; Humans; Lumbar V	2011
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2012, Mar-08, Volume: 102, Issue:5 Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases,	2012
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44 Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents,	2002
A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. The Journal of rheumatology, 2003, Volume: 30, Issue:1 Topics: Adult; Aged; Alendronate; Bone Density; Calcium; Cost-Benefit Analysis; Estrogen Replacement Therapy	2003
[Vertebral body fracture as incidental finding in thoracic radiography. Family physician usually does not learn about it]. MMW Fortschritte der Medizin, 2003, Feb-20, Volume: 145, Issue:8 Topics: Bone Density; Diphosphonates; Double-Blind Method; Etidronic Acid; Family Practice; Female; Follow-U	2003
Effects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case report. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2003, Volume: 8, Issue:2 Topics: Adult; Back Pain; Bone Density; Drug Therapy, Combination; Etidronic Acid; Humans; Hydroxycholecalci	2003
[For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year]. MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19 Topics: Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteop	2003
[To treat effectively without delay. The data on fractures decisive]. MMW Fortschritte der Medizin, 2003, May-22, Volume: 145, Issue:21 Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dipho	2003
[Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years]. MMW Fortschritte der Medizin, 2003, Jun-05, Volume: 145, Issue:23 Topics: Aged; Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans	2003
Efficacy of risedronate on clinical vertebral fractures within six months. Current medical research and opinion, 2004, Volume: 20, Issue:4 Topics: Body Height; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; R	2004
[Consistent therapeutic success in osteoporosis]. Krankenpflege Journal, 2004, Volume: 42, Issue:3-4 Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans;	2004
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschritte der Medizin, 2004, May-20, Volume: 146, Issue:21 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr	2004
[Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient]. MMW Fortschritte der Medizin, 2004, May-27, Volume: 146, Issue:22 Topics: Age Factors; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Hip F	2004
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)]. MMW Fortschritte der Medizin, 2004, Aug-05, Volume: 146, Issue:31-32 Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou	2004
[Update 2004. Osteoporosis--management--current status]. Krankenpflege Journal, 2004, Volume: 42, Issue:7-10 Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem	2004
A case of post-pregnancy osteoporosis-related spinal fractures in association with ankylosing spondylitis. Clinical rheumatology, 2005, Volume: 24, Issue:4 Topics: Adult; Bed Rest; Calcitonin; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; F	2005
Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology, 2005, Nov-08, Volume: 65, Issue:9 Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Causality; Clinical Trials as Topic; Etidr	2005
Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2005, Volume: 27, Issue:8 Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Bone Diseas	2005
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:7 Topics: Age Factors; Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Health Care Costs; Huma	2006
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice]. MMW Fortschritte der Medizin, 2007, Mar-29, Volume: 149, Issue:13 Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp	2007
High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman. Wiener medizinische Wochenschrift (1946), 2007, Volume: 157, Issue:15-16 Topics: Absorptiometry, Photon; Accidental Falls; Administration, Oral; Biopsy; Bone and Bones; Bone Density	2007
How to assess drug efficacy in osteoporosis. Lancet (London, England), 1995, Mar-25, Volume: 345, Issue:8952 Topics: Bone Density; Calcitonin; Drug Approval; Estrogens; Etidronic Acid; Fractures, Bone; Humans; Osteopo	1995
Reversal of severe osteoporosis with vitamin B12 and etidronate therapy in a patient with pernicious anemia. Metabolism: clinical and experimental, 1994, Volume: 43, Issue:4 Topics: Aged; Anemia, Pernicious; Drug Therapy, Combination; Etidronic Acid; Follow-Up Studies; Humans; Male	1994
Osteoporotic vertebral collapse in a woman. The Practitioner, 1994, Volume: 238, Issue:1539 Topics: Aged; Back Pain; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Osteoporosis; Spinal	1994
Cyclic etidronate: has the rose lost its bloom? The American journal of medicine, 1993, Volume: 95, Issue:6 Topics: Bone Density; Bone Resorption; Drug Administration Schedule; Etidronic Acid; Humans; Spinal Fracture	1993
A comparison of the effectiveness and cost of treatment for vertebral fractures in women. British journal of rheumatology, 1995, Volume: 34, Issue:12 Topics: Aged; Calcitonin; Cost-Benefit Analysis; Estrogen Replacement Therapy; Etidronic Acid; Female; Human	1995
Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1996, Volume: 6, Issue:3 Topics: Absorptiometry, Photon; Adult; Biomarkers; Bone Density; Bone Resorption; Calcium; Creatinine; Etidr	1996
Preventing glucocorticoid-induced osteoporosis. The New England journal of medicine, 1997, Aug-07, Volume: 337, Issue:6 Topics: Bone Density; Calcium Carbonate; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids;	1997
Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Age and ageing, 1997, Volume: 26, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; Calcium Citrate; Dose-Response R	1997
Intermittent etidronate and corticosteroid-induced osteoporosis. The New England journal of medicine, 1997, Dec-25, Volume: 337, Issue:26 Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Etidronic Acid; Female; Humans; Male; Osteoporosis;	1997
Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: histomorphometry and X-Ray microanalysis evaluation. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1999, Volume: 14, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biopsy; Bone Density; Bone Remodeling; Calcium; Electron Probe Micro	1999
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. PharmacoEconomics, 1998, Volume: 14, Issue:5 Topics: Aged; Alendronate; Calcium; Cost-Benefit Analysis; Drug Therapy, Combination; Estradiol; Estrogen Re	1998
Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. Skeletal radiology, 2000, Volume: 29, Issue:5 Topics: Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthralgia; Diphosphonates; Etidronic Acid; Fo	2000
[A new bisphosphonate. A vertebral body fracture seldom remains alone]. MMW Fortschritte der Medizin, 2000, Jul-06, Volume: 142, Issue:26-27 Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal	2000
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist? Bone, 2000, Volume: 27, Issue:6 Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni	2000
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture]. MMW Fortschritte der Medizin, 2001, May-03, Volume: 143, Issue:18 Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged;	2001
[Fluorides and bisphosphonates in the treatment of osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru	2001
[Osteoporosis. Fracture as alarm signal]. MMW Fortschritte der Medizin, 2001, Oct-11, Volume: 143, Issue:41 Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenop	2001
A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in medicine, 2001, Nov-15, Volume: 20, Issue:21 Topics: Biometry; Endpoint Determination; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Rand	2001
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H	2001
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, May-28, Volume: 166, Issue:11 Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures;	2002
Osteoporosis after 60. BMJ (Clinical research ed.), 1990, Sep-08, Volume: 301, Issue:6750 Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Po	1990
Etidronate for postmenopausal osteoporosis. The New England journal of medicine, 1990, Oct-25, Volume: 323, Issue:17 Topics: Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Spinal Fractures	1990

etidronate and Hangman Fracture